Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden

被引：0
|
作者：
Prutz, C. [1 ]
Snedecor, S. [4 ]
Botteman, M. [4 ]
Trocio, J. [2 ]
Weinstein, D. [3 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Pfizer Inc, New York, NY USA
[3] Pfizer France, Paris, France
[4] Pharmerit N Amer, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70951-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A302 / A302
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS IN TREATING OVERACTIVE BLADDER WITH URGE INCONTINENCE IN WOMEN: A COMPARISON BETWEEN OXYBUTYNIN AND TOLTERODINE WITH EXPLORATORY ANALYSIS OF FESOTERODINE
    Schwartz, E. L.
    Hay, J. W.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A79 - A79
  • [22] COST-EFFECTIVENESS STUDY OF DIAGNOSTIC TOOLS FOR THE EVALUATION OF FEMALE WITH OVERACTIVE BLADDER SYMPTOMS
    Lopez-Fando Lavalle, L.
    Jimenez Cidre, M. A.
    Esteban Fuertes, M.
    Prieto Chaparro, L.
    Arlandis Guzman, S.
    Franco de Castro, A.
    Salinas Casado, J.
    Castro-Diaz, D.
    Gutierrez Ruiz, C.
    Ifu, G.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2012, 31 (06) : 1007 - 1008
  • [23] THE COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN SWEDEN
    JOHANNESSON, M
    [J]. PHARMACOECONOMICS, 1995, 7 (03) : 242 - 250
  • [24] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelrahman, Abdelmageed
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1221 - 1221
  • [25] Cost-Effectiveness of Third-Line Therapies for Overactive Bladder
    Cohen S.A.
    [J]. Current Bladder Dysfunction Reports, 2018, 13 (3) : 153 - 157
  • [26] COST-EFFECTIVENESS OF MIRABEGRON COMPARED WITH ANTIMUSCARINICS FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED KINGDOM
    Maman, K.
    Neine, M.
    Briquet, B.
    Nazir, J.
    Odeyemi, I. A. O.
    Hakimi, Z.
    Garnham, A.
    Aballea, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A633 - A634
  • [27] COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION AND BOTULINE TOXIN A TREATMENT FOR PATIENTS WITH OVERACTIVE BLADDER
    Leong, R. K.
    Weil, E. H. J.
    Van Kerrebroeck, P. E. V.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 242 - 242
  • [28] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelmageed Abdelrahman
    [J]. International Urogynecology Journal, 2018, 29 : 1221 - 1221
  • [29] COST-EFFECTIVENESS OF SACRAL NEUROMODULATION IN THE TREATMENT OF IDIOPATHIC WET REFRACTORY OVERACTIVE BLADDER IN ITALY
    D'Ausilio, A.
    Bertapelle, P.
    Vottero, M.
    Del Popolo, G.
    Giannantoni, A.
    Ostardo, E.
    Spinelli, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A357 - A357
  • [30] Flexible dose fesoterodine in the treatment of overactive bladder (OAB)
    Tubaro, Andrea
    De Nunzio, Cosimo
    [J]. BJU INTERNATIONAL, 2013, 112 (03) : 281 - 282
12345